ライフサイエンスコーパス: bioabsorbable

1 baseline probing depth was 7.8+/-1.1 mm for bioabsorbable and 7.9+/-1.3 mm for nonresorbable barrier

2 The present data suggest bioabsorbable and nonresorbable barriers provide similar

3 ade calcium sulfate (CS) is a biocompatible, bioabsorbable, and clinically versatile ceramic for use

4 BioSTAR is a novel, bioabsorbable, atrial septal repair implant.

5 ion defects with a new polylactic-acid-based bioabsorbable barrier (test treatment) or a non-absorbab

6 atients were treated with a combination of a bioabsorbable barrier and coronally advanced flap techni

7 ded tissue regeneration therapy (GTR) with a bioabsorbable barrier composed of polylactic acid.

8 ares the outcomes obtained from the use of a bioabsorbable barrier device in combination with deminer

9 he effectiveness and the predictability of a bioabsorbable barrier in the treatment of human recessio

10 defects were treated by flap debridement and bioabsorbable barrier membrane augmentation.

11 to evaluate the regenerative potential of 2 bioabsorbable barrier membranes without the use of graft

12 The efficacy of the bioabsorbable barrier needs to be equal to, if not bette

13 At 6 months, sites treated with bioabsorbable barrier revealed 4.6+/-1.7 mm gain of clin

14 ustained release of 4% doxycycline through a bioabsorbable barrier would enhance the regenerative out

15 nt of DFDBA (GTR+DFDBA, or test group) and a bioabsorbable barrier, while the contralateral side rece

16 ent trends in therapy encourage the use of a bioabsorbable barrier.

17 non-resorbable barriers and polylactic acid bioabsorbable barriers in humans with intrabony defects

18 88.2 +/- 9.6); the seven sites treated with bioabsorbable barriers resulted in 5.9 +/- 1.2 mm of CAL

19 A new bioabsorbable bilayer collagen membrane that readily ada

20 and cementum regeneration following use of a bioabsorbable, calcium carbonate biomaterial in conjunct

21 Bioabsorbable cardiac matrix (BCM) is a novel device tha

22 cross-linking into a hydrogel and forming a bioabsorbable cardiac scaffold.

23 ed as an exciting new biomaterial for use in bioabsorbable cardiac stents.

24 This study examined a synthetic bioabsorbable carrier for BMP used in osseous defects ar

25 o test the hypothesis that HA can serve as a bioabsorbable carrier for other substrates as well as it

26 The data indicated the bioabsorbable collagen and copolymer membranes resulted

27 n flap debridement (OFD), MBA, or MBA with a bioabsorbable collagen membrane (guided tissue regenerat

28 one of two possible treatment pairs, either bioabsorbable collagen membrane (Type I bovine tendon co

29 lone, bone graft [BG], and bone graft plus a bioabsorbable collagen membrane [BG + C]), anatomic fact

30 y compared the efficacy of a porcine-derived bioabsorbable collagen membrane and an expanded polytetr

31 ose of this study was to assess the use of a bioabsorbable collagen membrane as a barrier device in r

32 A bioabsorbable collagen membrane was secured over the con

33 A bioabsorbable collagen membrane was secured over the imp

34 his newly introduced MBA, with and without a bioabsorbable collagen membrane, for the treatment of ma

35 bovine bone with platelet-rich plasma and a bioabsorbable collagen membrane.

36 allograft/xenograft mixture and covered by a bioabsorbable collagen membrane.

37 of combined induced perio-endo lesions using bioabsorbable collagen membranes alone or in combination

38 Several bioabsorbable collagen membranes are either currently av

39 hogenetic protein-2 (rhBMP-2) delivered on a bioabsorbable collagen sponge (ACS) compared to placebo

40 ollagen wound dressing material) or control (bioabsorbable collagen wound dressing material only) gro

41 randomly assigned to the test (Putty P15 and bioabsorbable collagen wound dressing material) or contr

42 -derived growth factor-BB (rhPDGF-BB) with a bioabsorbable collagen wound-healing dressing and a coro

43 reated with 0.3 mg/ml rhPDGF-BB + beta-TCP + bioabsorbable collagen wound-healing dressing; contralat

44 randomly selected for treatment with either bioabsorbable demineralized bone allograft membrane or e

45 ar furcation invasion defects using either a bioabsorbable demineralized laminar bone allograft membr

46 Bioabsorbable devices and percutaneously implanted valve

47 tly less acute thrombogenicity compared with bioabsorbable EES and biolimus-eluting stents.

48 imus eluting stents (EES), thick-strut fully bioabsorbable EES, thick-strut biodegradable polymer met

49 nocytes/macrophages at 14 days compared with bioabsorbable EES.

50 m adjunct antithrombotic pharmacotherapy for bioabsorbable EES.

51 ls and barrier membranes (non-resorbable and bioabsorbable) have been used in GBR.

52 e pipetted onto a 3-mm diameter x 2-mm thick bioabsorbable hemostatic gelatin and placed onto the sur

53 Our approach reveals that 3D printing of bioabsorbable implants containing anti-cancer drugs coul

54 surgical implantation of a space-providing, bioabsorbable, macroporous, polyglycolic acid-trimethyle

55 icity between the Magmaris sirolimus-eluting bioabsorbable magnesium scaffold and the Absorb bioresor

56 ut thickness, the Magmaris sirolimus-eluting bioabsorbable magnesium scaffold was significantly less

57 ak; however, if surgeons desire to buttress, bioabsorbable material is the most common type used.

58 Studies on other bioabsorbable materials using a new fabrication techniqu

59 There has been an increase in the use of bioabsorbable materials which do not require a second su

60 ologous mesenchymal stem cells, applied in a bioabsorbable matrix, can heal the fistula.

61 ek (test or GPN group) or with a polylactide bioabsorbable membrane alone (control or GA group).

62 the same flap surgery followed by use of the bioabsorbable membrane alone (GTR, or control group).

63 ffected by using an osteoinductive DFDBA and bioabsorbable membrane and membrane stabilization.

64 es (10 patients) were treated with DFDBA and bioabsorbable membrane before placing endosseous implant

65 P), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (G

66 This bioabsorbable membrane has been shown to be effective in

67 No reports exist on the use of a bioabsorbable membrane in combination with a demineraliz

68 ed freeze-dried bone allograft (DFDBA) and a bioabsorbable membrane is significantly less than the in

69 A bioabsorbable membrane of glycolide and lactide copolyme

70 ts in 24 patients were treated with either a bioabsorbable membrane plus twice daily postsurgical nap

71 t of DFDBA in the furcation defect under the bioabsorbable membrane resulted in a greater mean reduct

72 In the test defects, a bioabsorbable membrane was positioned.

73 A surgical technique involving a bioabsorbable membrane was used to treat localized bucca

74 Allograft (DMFDB) and a bioabsorbable membrane were employed.

75 This study shows that the use of a bioabsorbable membrane will predictably and significantl

76 polytetrafluoroethylene (ePTFE), GTR using a bioabsorbable membrane with or without demineralized fre

77 eatment of Class II furcation lesions with a bioabsorbable membrane with or without the adjunctive us

78 treatment of human gingival recession with a bioabsorbable membrane with or without the use of DFDBA

79 Ten sites received a collagen bioabsorbable membrane, 10 sites received acellular derm

80 t with a bioabsorbable synthetic bone graft, bioabsorbable membrane, and minocycline root conditionin

81 ients were treated with either a polylactide bioabsorbable membrane, demineralized freeze-dried bone

82 en defect received a poly(lactic acid)-based bioabsorbable membrane, while the paired defect received

83 Each patient was treated by GTR using a bioabsorbable membrane.

84 Contrary to this, bioabsorbable membranes allowed earlier anastomosis of t

85 ylene [ePTFE] titanium reinforced membranes, bioabsorbable membranes alone, bioabsorbable membranes w

86 y superior to that obtained with polylactide bioabsorbable membranes alone.

87 e are little data evaluating the efficacy of bioabsorbable membranes in the treatment of intrabony de

88 GTR therapy utilizing bioabsorbable membranes offers the advantages of prevent

89 ed membranes, bioabsorbable membranes alone, bioabsorbable membranes with a bone replacement graft [c

90 t, second and fourth premolars, received the bioabsorbable membranes, made of glycolide and lactide p

91 GTR) procedures using both nonresorbable and bioabsorbable membranes.

92 Bioabsorbable metal zinc (Zn) is a promising new generat

93 Electrospun nonwoven bioabsorbable nanofibrous membranes of poly(lactide-co-g

94 udy was to evaluate the efficacy of nonwoven bioabsorbable nanofibrous membranes of poly(lactideco-gl

95 ibroblast growth factor (bFGF) was used in a bioabsorbable, non-hydroxyapatite, calcium phosphate cem

96 and 2- to 3-wall intrabony defects with the bioabsorbable periodontal membrane.

97 on following guided tissue regeneration with bioabsorbable polylactic acid barriers.

98 THE EFFICACY OF A BIOABSORBABLE polylactic acid based barrier was evaluate

99 clinical effects of DFDBA associated with a bioabsorbable (polylactic acid) barrier membrane in the

100 techniques in intrabony defects utilizing a bioabsorbable, polylactic acid (PLA) barrier or the non-

101 estigate the relative safety and efficacy of bioabsorbable polymer (BP)-based biolimus-eluting stents

102 A bioabsorbable polymer barrier of poly(DL-lactide) was us

103 uccessful GBR outcomes may be possible using bioabsorbable polymer barriers.

104 y of 2 dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) (Bo

105 INTERPRETATION: The sirolimus-eluting bioabsorbable polymer stent was non-inferior to the ever

106 livery of everolimus by a unique directional bioabsorbable polymer system utilizing the SYNERGY stent

107 y and efficacy of durable polymer-based DES, bioabsorbable polymer-based biolimus-eluting stents (BES

108 Cr-EES may have a better safety profile than bioabsorbable polymer-based DES.

109 Bioabsorbable polymer-coated drug-delivery systems may r

110 flet heart valves were fabricated from novel bioabsorbable polymers and sequentially seeded with auto

111 y of fluoropolymer-coated CoCr-EES, DES with bioabsorbable polymers, and fully bioresorbable scaffold

112 ither more biocompatible durable polymers or bioabsorbable polymers.

113 onstruction and the use of biocompatible and bioabsorbable polymers.

114 : open flap debridement only (OFD), OFD with bioabsorbable porcine-derived collagen membrane (BG), or

115 This was held in place by a bioabsorbable retaining suture around the root, and the

116 ronary delivery of an innovative, injectable bioabsorbable scaffold (IK-5001), to prevent or reverse

117 based drug-eluting metallic stents and fully bioabsorbable scaffolds to date.

118 The bioabsorbable, space-providing, macroporous PGA-TMC memb

119 combines the best behaviors of both current bioabsorbable stent materials: iron and magnesium.

120 late and secured to the recipient sites with bioabsorbable sutures.

121 enerative therapy by open debridement with a bioabsorbable synthetic bone graft, bioabsorbable membra

122 study was to assess the performance of a new bioabsorbable, synthetic polyglycolic acid/trimethylene

123 Sponges of bioabsorbable type I collagen membrane were exposed to p

124 treated with either doxcycycline hyclate in bioabsorbable vehicle (DHV) or with vehicle control (VC)

125 The addition of doxycycline hyclate in a bioabsorbable vehicle used as a locally delivered drug d